According to the Zhitong Finance App, Qingcheng New Pharmaceutical-B (02396) announced interim results for the six months ended June 30, 2026. The group's other revenue and earnings were RMB 999,000, up 59.08% year on year; parent company owners should account for losses of RMB 122 million, up 40.65% year on year; basic and diluted loss of 1.04 yuan per share; proposed interim dividend of HK$0.50 per share.

According to the announcement, the increase in other revenue and earnings was mainly due to the increase in interest income from bank deposits driven by net proceeds from the global sale in December 2025.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.